Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 59

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 59
---
 per Unit (assuming the sale of all       
 securities offered hereby and assuming no exercise of the IPO Warrants issued in connection with this Primary Offering), after deducting 
 estimated offering expenses payable by us as if the sale of the securities had occurred on June 30, 2025.                                |

You should read this information together with
our consolidated financial statements and related notes, as well as the information set forth under the headings “Use of Proceeds”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere
in this prospectus.

|                                                                                                                                          |     | As of June 30, 
 2025           |         |   |     |           |         |   |
|:-----------------------------------------------------------------------------------------------------------------------------------------|:----|:---------------|--------:|:--|:----|:----------|--------:|:--|
| U.S. dollars in thousands                                                                                                                |     | Actual         |         |   |     | Pro Forma |         |   |
|                                                                                                                                          |     | -Unaudited     |         |   |     |           |         |   |
| Stockholders’ equity:                                                                                                                    |     |                |         |   |     |           |         |   |
| Preferred stock, $0.001 par value per share; 10,000,000                                                                                  
 shares authorized, none shares issued and outstanding; 10,000,000 shares authorized and none shares issued and outstanding, pro forma;   
 10,000,000 shares authorized and none shares issued and outstanding, pro forma as adjusted                                               |     | $              |       - |   |     |           |       - |   |
| Common stock, $0.001 par value per share; 250,000,000                                                                                    
 shares authorized, 60,729,100 shares issued and outstanding; 250,000,000 shares authorized and 63,854,100 shares issued and outstanding, 
 pro forma                                                                                                                                |     | $              |      61 |   |     |           |      64 |   |
| Additional paid-in capital                                                                                                               |     | $              |  31,652 |   |     |           |  36,049 |   |
| Accumulated deficit                                                                                                                      |     | $              | (13,119 | ) |     |           | (13,119 | ) |
| Total shareholders’ equity                                                                                                               |     | $              |  18,594 |   |     |           |